gemcitabine

5 · 20 / page

Ask MedXY AI

Latest news

Tag

GastroenterologyBiliary tract cancercisplatin

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

By MedXY|Jul 12, 2026

A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

GastroenterologyBiliary tract cancer

gemcitabine

Latest news

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial